| Literature DB >> 35528500 |
Niharika Kotian1, Erulappan Muthu Ganapathi Subramanian1, Ganesh Jeevanandan1.
Abstract
Aim: To systematically identify and evaluate the available literature based on the sedative effect of oral midazolam compared with midazolam administered intranasally and also compare their effect on behavior of pediatric dental patients. Objective: This systematic review compares the sedative effect and the effect on behavior with oral midazolam and intranasal midazolam.Entities:
Keywords: Midazolam; Pediatric dentistry; Sedation; Systematic review
Year: 2022 PMID: 35528500 PMCID: PMC9016920 DOI: 10.5005/jp-journals-10005-2117
Source DB: PubMed Journal: Int J Clin Pediatr Dent ISSN: 0974-7052
Fig. 1Prisma flowchart showing included studies
Characteristics of excluded studies
|
|
|
|
|---|---|---|
|
| Yildirim et al. (2006) | Oral midazolam and nasal midazolam was used as a premedication and not for routine dental procedure. |
|
| Klein EJ et al. (2011) | Comparison of aerosolized intranasal or buccal midazolam with oral midazolam for laceration repair and not for routine dental treatment. |
|
| Heard C et al. (2010) | Four sedative techniques of midazolam are compared for dental surgery and not for routine dental procedures. |
|
| Tschirch et al. (2007) | Not evaluated for routine dental procedure. |
|
| Kogan et al. (2002) | Oral midazolam and nasal midazolam was used as a premedication and not for routine dental procedure. |
|
| Malinovsky et al. (1992) | Oral midazolam and nasal midazolam was used as a premedication and not for routine dental procedure. |
|
| Tolksdorf et al. (1991) | Oral midazolam and nasal midazolam was used as a premedication and not for routine dental procedure. |
|
| Connors et al. (1994) | Comparison of oral midazolam and nasal midazolam for laceration repair and not for routine dental procedure. |
|
| Manoj et al. (2017) | Oral midazolam and nasal midazolam was used as a premedication and not for routine dental procedure. |
Characteristics of included studies
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||
|
|
| Randomized controlled trial | 100 children in the age-group of 1.5 to 6 years. | Oral midazolam 0.3 mg/kg in hydroxyzine paomate suspension (50) (along with 40% nitrous oxide and 60% oxygen) | Intranasal midazolam 0.2 mg/kg(50) (along with 40% Nitrous oxide and 60% Oxygen) | i) Global behavior rating scale | i) Behavior |
|
|
| Single-blinded randomized controlled trial | 40 children in the age-group of 24 to 72 months | Oral midazolam 0.7 mg/kg(20) | Intranasal midazolam 0.3 mg/kg(20) | i) Onset of sedation | i) Behavior |
|
|
| Double-blinded randomized controlled crossover trial | 31 children in the age-group of 42 to 84 months | Oral midazolam 0.5 mg/kg (cherry syrup) and intranasal saline placebo | Intranasal midazolam 0.3 mg/kg and oral placebo (cherry syrup) | i) Modified Houpt behavior rating scale | i) Behavior |
|
|
| Randomized controlled crossover trial | 30 children in the age-group of 3-6 years | 0.2 mg/kg of oral midazolam in syrup form and 30% nitrous oxide 70% oxygen(30) | 0.1 mg/kg of intranasal midazolam spray and 30% nitrous oxide 70% oxygen (30) | i) Patient's acceptability of drug | i) Behavior and alertness |
General information on the results of included studies
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
| 1. | Hartgraves and Primosch (1994) | Intranasal midazolam (0.2 mg/kg) Oral midazolam (0.3 mg/kg) in hydroxyzine paomate suspension (along with 40% Nitrous oxide and 60% oxygen) | NA | Intranasal midazolam:62% showed a satisfactory behavioral effect on sedation | Oral midazolam:66% showed a satisfactory behavioral effect on sedation | Intranasal midazolam:31/50 treatment completed successfully | Oral midazolam:33/50 treatment completed successfully |
| No statistically significant difference in the Global behavior rating scale scores was observed | No statistically significant difference in the success of treatment was observed. | ||||||
| 2. | Lee-Kim et al. (2004) | (0.3 mg/kg) intranasal midazolam 0.7 mg/kg Oral midazolam | NA | Intranasal midazolam: Between 25 and 30 minutes subjectshowed more movement and less sleep and between 30 and 35 minutes significant changes toward waking after administration of sedation. | Oral midazolam: Significant change toward waking was seen between 30 to 35 minute after administration of sedation. | Intranasal midazolam: 20/20 treatment was completed successfully. | Oral midazolam: 20/20 treatment was completed successfully. |
| There was no statistically significant difference in the overall behavior scores in the Houpt behavior scale between the groups analyzed using multivariate ANOVA. | No statistically significant difference in the success of treatment between the groups. | ||||||
| 3. | Johnson et al. (2010) | Intranasal midazolam (0.3 mg/kg) Oral midazolam(0.5 mg/kg) | Intranasal midazolam:There was no statistically significant difference in the overall behavior scores in the Houpt behavior scale between the groups analyzed using multivariate ANOVA. | Oral midazolam: there was significantly higher scores in the modified Houpt behavior rating scale only for first 15 minutes of appointment. | Intranasal midazolam:31/31 treatment completed successfully | Oral midazolam:31/31 treatment completed successfully | |
| There was no statistically significant difference in the overall behavior scores in the Modified Houpt behavior scale between the groups. | No statistically significant difference in the success of treatment between the groups. | ||||||
| 4. | Musani and Chandan (2015) | Intranasal midazolam 0.1 mg/kg | Ellis sedation score: | Intranasal midazolam: According to Houpt's behavior rating scale: | Oral midazolam: | Intranasal midazolam: | Ora |
| No statistically significant difference in Ellis sedation score of treatment between the groups. | There was no statistically significant difference in the overall behavior scores in the Houpt behavior scale between the groups. | No statistically significant difference in the success of treatment between the groups. | |||||
Fig. 2Risk of bias Graph: judgement about each risk of bias item presented as percentage among included studies
Fig. 3Risk of bias summary: Judgement about each risk of bias item for each included study